Johnson & Johnson (JNJ) Position Raised by Ancora Inverness LLC
Ancora Inverness LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% during the second quarter, Holdings Channel reports. The fund owned 42,441 shares of the company’s stock after buying an additional 1,583 shares during the period. Johnson & Johnson makes up about 1.9% of Ancora Inverness LLC’s portfolio, making the stock its 9th largest position. Ancora Inverness LLC’s holdings in Johnson & Johnson were worth $5,148,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Americafirst Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth approximately $101,000. INR Advisory Services LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth approximately $150,000. Capital Asset Advisory Services LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth approximately $202,000. NewSquare Capital LLC boosted its stake in shares of Johnson & Johnson by 4.9% in the second quarter. NewSquare Capital LLC now owns 1,791 shares of the company’s stock worth $217,000 after buying an additional 83 shares in the last quarter. Finally, Shayne & CO. LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth approximately $219,000. 65.32% of the stock is owned by hedge funds and other institutional investors.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.59% during midday trading on Friday, hitting $117.56. 5,640,519 shares of the stock traded hands. The stock has a market cap of $321.63 billion, a price-to-earnings ratio of 21.91 and a beta of 0.62. Johnson & Johnson has a 12-month low of $94.28 and a 12-month high of $126.07. The company’s 50 day moving average price is $118.72 and its 200-day moving average price is $117.37.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.06. The firm earned $18.50 billion during the quarter, compared to analyst estimates of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. On average, equities research analysts expect that Johnson & Johnson will post $6.69 EPS for the current year.
A number of brokerages have commented on JNJ. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 target price for the company in a report on Friday, August 5th. BMO Capital Markets reaffirmed an “outperform” rating and set a $132.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 20th. Deutsche Bank AG reaffirmed a “hold” rating and set a $142.00 target price (up from $125.00) on shares of Johnson & Johnson in a report on Thursday, July 21st. Vetr raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $124.21 target price for the company in a report on Monday, August 8th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, September 7th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $120.19.
In related news, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Dominic J. Caruso sold 41,146 shares of the business’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.